KYOWA HAKKO KIRIN - ARQ-197 Enters Japanese Ph III - Success Will Boost KHK’s Onco Ambitions!
Kyowa Hakko Kirin announced to initiate Ph III JP trial for ARQ-197 (Ph II, c-Met inhibitor, advance or metastatic NSCLC, oral). JP Ph III design will follow JP Ph II and international Ph II trails that compared overall survival (OS) of patients treated with ARQ 197 and Tarceva (erlotinib) vs. placebo and Tarceva. Data presented earlier at ASCO & ESMO suggest favorable outcome in Ph III. ARQ-197, if reaches market, will be targeting ~ 30,000 patients in Japan and expecting a generous 10% discounted launch price to Tarceva with an initial penetration on 10%, which will grow to ~50% by 2018 of total potential market.
This report analyzes NSCLC market, current therapy paradigm and opportunity for ARQ 197 in Japan.
This report analyzes NSCLC market, current therapy paradigm and opportunity for ARQ 197 in Japan.
COMPANIES MENTIONED
Kyowa Hakko Kirin, 4151
Kyowa Hakko Kirin, 4151
